Lisaftoclax: all 31 studies that test it
Page 1 of 1. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.
- Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLLNot yet recruitingNCT07831395Phase 2
- Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy FailureEnrolling by invitationNCT07813390Phase 2
- A Single-center, Prospective, Exploratory Clinical StudyNot yet recruitingNCT07795099Not applicable
- Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)Not yet recruitingNCT07717580Phase 2
- Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of RelapseNot yet recruitingNCT07686965Phase 3
- Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted TherapyNot yet recruitingNCT07684950Phase 2
- Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive ChemotherapyEnrolling by invitationNCT07651176Phase 2/3
- Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive ChemotherapyEnrolling by invitationNCT07651163Phase 2/3
- Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell LymphomaNot yet recruitingNCT07601607Phase 1/2
- Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia PatientsNot yet recruitingNCT07597941Phase 2/3
- Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell LymphomaNot yet recruitingNCT07459608Phase 2
- Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRecruitingNCT07272499Phase 2
- Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCLRecruitingNCT07255963Phase 2
- Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).RecruitingNCT06641414Phase 3
- A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid LeukemiaRecruitingNCT06389292Phase 3
- A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.RecruitingNCT06319456Phase 3
- Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaRecruitingNCT06265545Not applicable
- A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.RecruitingNCT06182969Phase 1/2
- Global Trial in APG2575 for Patients With CLL/SLLRecruitingNCT06104566Phase 3
- APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid TumorsRecruitingNCT05701306Phase 1/2
- Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALLRecruitingNCT05495035Phase 1
- Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLRecruitingNCT05147467Phase 2
- A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)RecruitingNCT04964518Phase 1/2
- APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT04942067Phase 1/2
- A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLRecruitingNCT04496349Phase 2
- Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLLRecruitingNCT04215809Phase 1
- APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic MalignanciesRecruitingNCT03537482Early Phase 1
- A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic LeukemiaWithdrawnNCT07428486Phase 1
- The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy SubjectsCompletedNCT05517616Phase 1
- APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström MacroglobulinemiaCompletedNCT04260217Phase 1
- A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic MalignanciesActive, not recruitingNCT03913949Phase 1